Milestone Pharmaceuticals' stock fell 50% after the FDA's CRL for CMC issues, but the drug Etripamil has shown efficacy and ...

TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone ...

Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA.

Milestone Pharmaceuticals Inc.’s MIST share price has surged by 11.94%, which has investors questioning if this is right time to sell.

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report) was downgraded by analysts at TD Securities from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday,BayStreet ...

Milestone Pharmaceuticals (NASDAQ:MIST – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued on Friday,Benzinga reports. They ...

TD Securities downgraded Milestone Pharmaceuticals (NASDAQ:MIST) to "Hold" and suspended its price target, citing regulatory uncertainty and commercialization challenges for its lead drug, etripamil, ...

H.C. Wainwright lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $10 from $25 and keeps a Buy rating on the shares after ...

Milestone Pharmaceuticals (MIST – Research Report) received a Hold rating and price target from TD Cowen analyst Ritu Baral today. The ...